APOLLO: A Phase 3 Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Patisiran (ALN-TTR02) in Transthyretin (TTR)-Mediated Polyneuropathy (Familial Amyloidotic Polyneuropathy-FAP)

Trial Profile

APOLLO: A Phase 3 Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Patisiran (ALN-TTR02) in Transthyretin (TTR)-Mediated Polyneuropathy (Familial Amyloidotic Polyneuropathy-FAP)

Completed
Phase of Trial: Phase III

Latest Information Update: 20 Sep 2017

At a glance

  • Drugs Patisiran (Primary)
  • Indications Amyloid polyneuropathy
  • Focus Registrational; Therapeutic Use
  • Acronyms APOLLO
  • Sponsors Alnylam Pharmaceuticals
  • Most Recent Events

    • 20 Sep 2017 Results published in an Alnylam Pharmaceuticals media release.
    • 20 Sep 2017 According to an Alnylam Pharmaceuticals media release, data will be presented at the 1st European ATTR Amyloidosis Meeting on November 2,2017.
    • 20 Sep 2017 According to an Alnylam Pharmaceuticals media release, based on positive results of this trial company expects to file its first New Drug Application in late 2017 and first Marketing Authorisation Application shortly thereafter in early 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top